Shattuck Labs (NASDAQ:STTK – Get Free Report) is one of 847 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Shattuck Labs to similar companies based on the strength of its profitability, valuation, dividends, earnings, analyst recommendations, risk and institutional ownership.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Shattuck Labs and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shattuck Labs | 1 | 0 | 9 | 3 | 3.08 |
| Shattuck Labs Competitors | 9772 | 15006 | 45342 | 1579 | 2.54 |
Shattuck Labs currently has a consensus target price of $13.70, suggesting a potential upside of 139.51%. As a group, “Biotechnology” companies have a potential upside of 95.22%. Given Shattuck Labs’ stronger consensus rating and higher possible upside, equities analysts clearly believe Shattuck Labs is more favorable than its rivals.
Insider & Institutional Ownership
58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Shattuck Labs and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shattuck Labs | N/A | -43.57% | -40.90% |
| Shattuck Labs Competitors | -9,054.47% | -198.89% | -30.64% |
Volatility & Risk
Shattuck Labs has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Shattuck Labs’ rivals have a beta of 1.11, suggesting that their average share price is 11% more volatile than the S&P 500.
Earnings & Valuation
This table compares Shattuck Labs and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Shattuck Labs | $1.00 million | -$48.81 million | -11.22 |
| Shattuck Labs Competitors | $691.65 million | $10.66 million | -10.15 |
Shattuck Labs’ rivals have higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
Shattuck Labs beats its rivals on 7 of the 13 factors compared.
About Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
